$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

$itci Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000119312517165965 Filed on May 10, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$114.7K	$95.29K	$0.00
YoY Change	-49.77%		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.250M	$6.310M	$5.060M
YoY Change	-3.4%	24.7%	34.22%
% of Gross Profit
Research & Development	$12.48M	$21.54M	$23.43M
YoY Change	-50.68%	-8.09%	25.77%
% of Gross Profit
Depreciation & Amortization	$50.00K	$50.43K	$47.97K
YoY Change	0.0%	5.13%	214.74%
% of Gross Profit
Operating Expenses	$18.73M	$27.85M	$28.50M
YoY Change	-41.04%	-2.28%	27.2%
Operating Profit	-$18.62M	-$27.75M	-$28.50M
YoY Change	-40.98%	-2.61%	27.22%
Interest Expense	$860.0K	$820.0K	$660.0K
YoY Change	21.13%	24.24%	500.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$17.76M	-$26.93M	-$27.84M
YoY Change	-42.4%	-3.27%	24.91%
Income Tax	$0.00	$1.600K
% Of Pretax Income
Net Earnings	-$17.76M	-$26.93M	-$27.84M
YoY Change	-42.4%	-3.26%	24.92%
Net Earnings / Revenue	-15478.95%	-28265.75%
Basic Earnings Per Share
Diluted Earnings Per Share	-$409.0K	-$620.6K	-$644.6K
COMMON SHARES
Basic Shares Outstanding	43.42M shares	43.41M shares	43.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$342.6M	$367.8M	$456.1M
YoY Change	-22.61%	-19.36%	93.92%
Cash & Equivalents	$29.59M	$23.60M	$37.24M
Short-Term Investments	$313.0M	$344.2M	$418.8M
Other Short-Term Assets	$6.100M	$3.800M	$6.800M
YoY Change	52.5%	-44.12%	423.08%
Inventory
Prepaid Expenses
Receivables	$61.94K	$68.20K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$348.8M	$371.6M	$462.9M
YoY Change	-21.93%	-19.71%	95.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$628.9K	$605.7K	$731.4K
YoY Change	-12.49%	-17.19%	30.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$75.77K	$75.77K	$71.88K
YoY Change	0.0%	5.41%	1.31%
Total Long-Term Assets	$704.7K	$681.4K	$803.3K
YoY Change	-11.3%	-15.17%	27.38%
TOTAL ASSETS
Total Short-Term Assets	$348.8M	$371.6M	$462.9M
Total Long-Term Assets	$704.7K	$681.4K	$803.3K
Total Assets	$349.5M	$372.3M	$463.7M
YoY Change	-21.91%	-19.71%	95.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.775M	$7.158M	$1.959M
YoY Change	-54.36%	265.33%	-57.17%
Accrued Expenses	$5.200M	$9.200M	$7.000M
YoY Change	-66.45%	31.43%	-30.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.963M	$16.32M	$8.947M
YoY Change	-64.07%	82.4%	-38.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.900M	$2.900M	$2.000M
YoY Change	26.09%	45.0%	900.0%
Total Long-Term Liabilities	$2.911M	$2.947M	$1.971M
YoY Change	28.87%	49.52%	1130.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.963M	$16.32M	$8.947M
Total Long-Term Liabilities	$2.911M	$2.947M	$1.971M
Total Liabilities	$9.874M	$19.27M	$10.92M
YoY Change	-54.37%	76.46%	-26.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$354.2M	-$336.4M	-$220.9M
YoY Change	40.7%	52.3%	99.82%
Common Stock	$694.2M	$689.7M	$673.7M
YoY Change	2.44%	2.38%	102.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$339.7M	$353.0M	$452.7M
YoY Change
Total Liabilities & Shareholders Equity	$349.5M	$372.3M	$463.7M
YoY Change	-21.91%	-19.71%	95.53%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$17.76M	-$26.93M	-$27.84M
YoY Change	-42.4%	-3.26%	24.92%
Depreciation, Depletion And Amortization	$50.00K	$50.43K	$47.97K
YoY Change	0.0%	5.13%	214.74%
Cash From Operating Activities	-$24.89M	-$16.40M	-$19.65M
YoY Change	84.37%	-16.54%	25.08%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	$28.50K	$3.874K
YoY Change	75.0%	635.62%	-99.26%
Acquisitions
YoY Change
Other Investing Activities	$30.95M	-$8.840M	$9.570M
YoY Change	10.18%	-192.37%	-114.46%
Cash From Investing Activities	$30.87M	-$8.870M	$9.570M
YoY Change	10.05%	-192.69%	-114.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	220.0K	160.0K
YoY Change	-94.74%	37.5%	-99.87%
NET CHANGE
Cash From Operating Activities	-24.89M	-16.40M	-19.65M
Cash From Investing Activities	30.87M	-8.870M	9.570M
Cash From Financing Activities	10.00K	220.0K	160.0K
Net Change In Cash	5.990M	-25.05M	-9.920M
YoY Change	-59.36%	152.52%	-125.13%
FREE CASH FLOW
Cash From Operating Activities	-$24.89M	-$16.40M	-$19.65M
Capital Expenditures	-$70.00K	$28.50K	$3.874K
Free Cash Flow	-$24.82M	-$16.43M	-$19.65M
YoY Change	84.4%	-16.41%	21.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43420478	shares
CY2015Q1	itci	Net Proceeds From Public Offering NetProceedsFromPublicOffering	121800000
CY2015Q3	us-gaap	Share Price SharePrice	43.50
CY2015Q3	itci	Net Proceeds From Public Offering NetProceedsFromPublicOffering	327400000
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37240565
CY2017Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	21600000
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	300000
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2599198
CY2017Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	356864000
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43415728	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43415728	shares
CY2017Q1	us-gaap	Assets Assets	372292306
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000
CY2017Q1	us-gaap	Assets Current AssetsCurrent	371610858
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	689723391
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	344475000
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2017Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	344183051
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23598325
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	68200
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	4342
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7157746
CY2017Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2121795
CY2017Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7039115
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-291708
CY2017Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2946573
CY2017Q1	us-gaap	Liabilities Liabilities	19265229
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	372292306
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16318656
CY2017Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	12700000
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	75765
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	605683
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3204881
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.61
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	353027077
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.42
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2302100	shares
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-336408948
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3761282
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3613286	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.42
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3613286	shares
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47159303
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	25500000
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	331000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2548769
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	346182000
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43292906	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43292906	shares
CY2016Q4	us-gaap	Assets Assets	388903495
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	388200116
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	685290815
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	335776000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	335458459
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48642225
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	94339
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	4329
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3754647
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1448394
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5329293
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-317239
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2868622
CY2016Q4	us-gaap	Liabilities Liabilities	13400956
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	388903495
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10532334
CY2016Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	10700000
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-141965
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Intra-Cellular Therapies, Inc.
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001567514
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25043900
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	731429
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	75765
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	627614
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3176383
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	375502539
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.63
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-309475366
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4005093
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3101032	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	129900000
CY2015Q1	itci	Share Issued During Period Shares Underwriters New Issues ShareIssuedDuringPeriodSharesUnderwritersNewIssues	661481	shares
CY2015Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	345200000
CY2015Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7935000	shares
CY2015Q3	itci	Share Issued During Period Shares Underwriters New Issues ShareIssuedDuringPeriodSharesUnderwritersNewIssues	1035000	shares
CY2016	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	25000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6310486
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
CY2017Q1	us-gaap	Depreciation Depreciation	50429
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26908051
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	19000
CY2017Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
CY2017Q1	us-gaap	Revenues Revenues	95287
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	27849444
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-26933582
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26931982
CY2017Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	93323
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8869524
CY2017Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	25531
CY2017Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	93103865
CY2017Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	47726
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	101944891
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2367851
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-26139
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3403099
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-243811
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27754157
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	224185
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	822175
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16398561
CY2016Q1	us-gaap	Depreciation Depreciation	47967
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27300309
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
CY2016Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	45675
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28498
CY2017Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	95000	shares
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.73
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	13903	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.60
CY2017Q1	dei	Trading Symbol TradingSymbol	ITCI
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21538958
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	Total shareholder return is determined by dividing the average share value of the Company's common stock over the 30 trading days preceding January 1, 2020 by the average share value of the Company's common stock over the 30 trading days beginning on March 8, 2017, with a deemed reinvestment of any dividends declared during the performance period.
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	224185
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.904	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021	pure
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4160678
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43385605	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P3Y
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	16.06
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	621157	shares
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2017Q1	itci	Maturity Period Of Liquid Investments To Be Considered As Cash Equivalents MaturityPeriodOfLiquidInvestmentsToBeConsideredAsCashEquivalents	Three months or less
CY2017Q1	itci	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2	P9Y9M18D
CY2017Q1	itci	Share Based Compensation Arrangement By Share Based Payment Award Canceled Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceledWeightedAverageRemainingContractualTerm	P9Y8M12D
CY2017Q1	itci	Available For Sale Securities Maturity Period AvailableForSaleSecuritiesMaturityPeriod	More than three months
CY2017Q1	itci	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm	P4Y
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-182418
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9918738
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	377000
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5064233
CY2016Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	32644315
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2356793
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	28497853
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-27841449
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27841449
CY2016Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	373642
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9568002
CY2016Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	541140
CY2016Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	42216191
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30660
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	326367
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1235043
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28497853
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	163683
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	656404
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19650423
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3874
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23433620
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	163683
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3592461
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43193857	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P3Y
CY2016Q1	itci	Percentage Of Amortization Expenses PercentageOfAmortizationExpenses	1.00	pure

Files In Submission

Name	View Source	Status
0001193125-17-165965-index-headers.html	Edgar Link	pending
0001193125-17-165965-index.html	Edgar Link	pending
0001193125-17-165965.txt	Edgar Link	pending
0001193125-17-165965-xbrl.zip	Edgar Link	pending
d378627d10q.htm	Edgar Link	pending
d378627dex311.htm	Edgar Link	pending
d378627dex312.htm	Edgar Link	pending
d378627dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
itci-20170331.xml	Edgar Link	completed
itci-20170331.xsd	Edgar Link	pending
itci-20170331_cal.xml	Edgar Link	unprocessable
itci-20170331_def.xml	Edgar Link	unprocessable
itci-20170331_lab.xml	Edgar Link	unprocessable
itci-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

2017 Q2 Form 10-Q Financial Statement

#000119312517165965 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI Intra-Cellular Therapies, Inc. Stock $itci

2017 Q2 Form 10-Q Financial Statement

#000119312517165965 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci